• Covid-19
  • Travel Protocols
  • Immigration & Customs Form
Sunday, May 25, 2025
SKNIS
  • Home
  • About
  • Press Releases
  • Parliament
  • In The News
  • Bills
No Result
View All Result
SKNIS
No Result
View All Result
Home Featured

WHO urges action to protect children from contaminated medicines

SKNISEditor by SKNISEditor
January 24, 2023
in Featured, Notices, Press Releases
Director-General’s opening remarks at the 10th meeting of the IHR Emergency Committee on COVID-19 – 13 January 2022
Share on FacebookShare on Twitter

Geneva, 23 January 2023 – WHO is releasing an urgent call to action to countries to prevent, detect and respond to incidents of substandard and falsified medical products.

Over the past four months, countries have reported on several incidents of over-the-counter cough syrups for children with confirmed or suspected contamination with high levels of diethylene glycol (DEG) and ethylene glycol (EG). The cases are from at least seven countries, associated with more than 300 fatalities in three of these countries. Most are young children under the age of five. These contaminants are toxic chemicals used as industrial solvents and antifreeze agents that can be fatal even taken in small amounts, and should never be found in medicines.

Related posts

Christophe Harbour and its Shareholders, the Darby Family and the Government of St. Kitts & Nevis, Announce the Sale of Marina Assets and Operations to Safe Harbor Marinas, LLC

Christophe Harbour and its Shareholders, the Darby Family and the Government of St. Kitts & Nevis, Announce the Sale of Marina Assets and Operations to Safe Harbor Marinas, LLC

May 23, 2025
CONTRIBUTION OPTION TO NEW PENSION PLAN ENSURES EQUITY AND SUSTAINABILITY

CONTRIBUTION OPTION TO NEW PENSION PLAN ENSURES EQUITY AND SUSTAINABILITY

May 23, 2025

Based on country reports, WHO has issued three global medical alerts addressing these incidents. The  Medical Product Alert N°6/2022 on 5 October 2022 focused on the outbreak in the Gambia, Medical Product Alert N°7/2022 on 6 November 2022 focused on Indonesia, and Medical Product Alert No1/2023 on 11 January 2023 focused on Uzbekistan.

WHO’s medical product alerts were rapidly disseminated to the national health authorities of all 194 WHO Member States.  These medical product alerts requested, inter alia: (a) the detection and removal of contaminated medicines from circulation in the markets, (b) increased surveillance and diligence within the supply chains of countries and regions likely to be affected, (c) immediate notification to WHO if these substandard products are discovered in-country; and otherwise inform the public of the dangers and toxic effects of the substandard medicines at issue.

Since these are not isolated incidents WHO calls on various key stakeholders engaged in the medical supply chain to take immediate and coordinated action.

WHO calls on regulators and governments to:

  • detect and remove from circulation in their respective markets any substandard medical products that have been identified in the WHO medical alerts referred to above as potential causes of deaths and disease;  
  • ensure that all medical products in their respective markets are approved for sale by competent authorities and obtainable from authorized/licensed suppliers;
  • assign appropriate resources to improve and increase risk-based inspections of manufacturing sites within their jurisdiction in accordance with international norms and standards;
  • increase market surveillance including risk-based targeted testing for medical products released in their respective markets including informal markets; and
  • enact and enforce, where relevant and as appropriate, laws and other relevant legal measures to help combat the manufacture, distribution and/or use of substandard and falsified medicines.

WHO calls on manufacturers of medicines to:

  • only purchase pharmaceutical grade excipients from qualified and bona fide suppliers;
  • conduct comprehensive testing upon receipt of supplies and before use in manufacture of finished products;
  • provide assurance of product quality including through certificates of analyses based on appropriate testing results; and
  • keep accurate, complete and proper records of purchase of materials, testing, manufacture, and distribution to facilitate traceability during investigations in case of incidents.

WHO urges all suppliers and distributors of medical products to:

  • always check for signs of falsification and physical condition of medicines and other health products they distribute and/or sell;
  • only distribute and/or sell medicines authorized by, and from sources approved by, competent authorities;
  • keep accurate, complete and proper records relating to the medicines and their distribution and/or sale; and
  • engage competent personnel to handle medicines and provide advice to the public on appropriate use of the medicines.

In addition, WHO will continue to work with the Member State Mechanism on substandard and falsified medical products in implementing its mandate to promote effective collaboration in the prevention, detection and response to substandard and falsified medical products to save lives.

Previous Post

SCASPA EARLY CLOSURE NOTICE

Next Post

WHO launches funding appeal to help a record number of people in complex, intersecting health emergencies

Next Post
Director-General’s opening remarks at the 10th meeting of the IHR Emergency Committee on COVID-19 – 13 January 2022

WHO launches funding appeal to help a record number of people in complex, intersecting health emergencies

WHAT'S HOT

Christophe Harbour and its Shareholders, the Darby Family and the Government of St. Kitts & Nevis, Announce the Sale of Marina Assets and Operations to Safe Harbor Marinas, LLC

Christophe Harbour and its Shareholders, the Darby Family and the Government of St. Kitts & Nevis, Announce the Sale of Marina Assets and Operations to Safe Harbor Marinas, LLC

May 23, 2025
CONTRIBUTION OPTION TO NEW PENSION PLAN ENSURES EQUITY AND SUSTAINABILITY

CONTRIBUTION OPTION TO NEW PENSION PLAN ENSURES EQUITY AND SUSTAINABILITY

May 23, 2025
SENIOR MINISTER DOUGLAS AFFIRMS THE ESSENTIAL ROLE OF SKNBS IN FACILITATING TRADE WITHIN AND BEYOND THE FEDERATION

DR. DOUGLAS HIGHLIGHTS HISTORIC IMPORTANCE AND GLOBAL REACH OF EXTRADITION BILL, 2025

May 23, 2025

BROWSE BY CATEGORIES

  • 2025
  • Attorney General, Ministry of Justice and Legal Affairs
  • Bills
  • Featured
  • Featured Ministry
  • Government Projects
  • Home Page Slider
  • In Focus
  • In The News
  • Interviews
  • Minister of Agriculture, Fisheries and Marine Resources; Cooperatives; Entrepreneurship and Creative Economy
  • Ministry of Education, Youth; Social Development; Gender Affairs; Aging and Disabilities
  • Ministry of Foreign Affairs, International Trade, Industry and Commerce and Consumer Affairs; Economic Development and Investment
  • Ministry of Public Infrastructure, Energy and Utilities; Domestic Transport; Information, Communication and Technology; and Posts
  • Ministry of Sustainable Development, Environment; Climate Action and Constituency Empowerment
  • Ministry of Tourism, Civil Aviation; International Transport; Employment and Labour; Urban Development
  • Notices
  • Parliament
  • PMO Press Releases
  • Press Conferences
  • Press Releases
  • Prime Ministers Office, Ministry of Finance; National Security; Citizenship and Immigration; Health and Social Security
  • Register of Voters
  • Round Table
  • The Cabinet Secretariat, Cabinet Secteatry
  • Uncategorized

LIKE US ON FACEBOOK

Facebook Pagelike Widget

LOCATION

St. Kitts Nevis Information Service
Government Headquarters
Chruch Street
Basseterre
St. Kitts
Tel:(869)467-1416

FOLLOW US

  • Government of St. Kitts & Nevis

© 2020 St. Kitts & Nevis Information Service. Developed by E-Government Unit

No Result
View All Result
  • Home

© 2020 St. Kitts & Nevis Information Service. Developed by E-Government Unit